Skip to main content

Determinants of Overall Survival in Metastatic Uveal Melanoma Identified

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, July 12, 2023 -- Factors associated with improved survival in metastatic uveal melanoma include female sex and use of anti‐cytotoxic T lymphocyte-associated antigen (CTLA)‐4 and anti‐programmed cell death protein 1 (PD-1) therapies, according to research published online June 29 in Cancer.

Patrick Demkowicz, from the Yale University School of Medicine in New Haven, Connecticut, and colleagues conducted a retrospective review of metastatic uveal melanoma patients at Yale (initial cohort) and Memorial Sloan Kettering (validation cohort). Eighty-nine patients were identified, including 71 and 18 in the initial and validation cohorts, respectively.

The researchers found better survival outcomes in association with female sex, anti-CTLA-4 therapy, and anti-PD-1 therapy, with adjusted hazard ratios for death of 0.40, 0.44, and 0.42, respectively; development of hepatic metastases and Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score ≥1 were associated with worse survival (hazard ratios, 2.86 and 2.84, respectively). After adjustment for sex and ECOG score, use of immune checkpoint inhibitors was associated with improved overall survival, with hazard ratios for death of 0.22 and 0.04, respectively.

"Metastatic uveal melanoma patients face limited treatment options and poor survival rates," the authors write. "Our findings suggest that immune checkpoint inhibitors may provide a viable treatment option for patients with metastatic uveal melanoma."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted July 2023

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.